Milestone Pharmaceuticals prices US$45 million offering of common shares

Date Closed

October 27, 2020

Lead Office



45.00 Million USD

On October 23, 2020, Milestone Pharmaceuticals Inc. priced an underwritten public offering of 3,810,097 of its common shares, as well as pre-funded warrants to purchase 4,761,903 of its common shares, for a total value of US$45 million. Milestone has expressed its intention to use the proceeds from the offering primarily to fund the clinical development of its lead product candidate etripamil, and for working capital, capital expenditures and other general corporate purposes.

Jefferies Finance LLC and Piper Sandler are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.

Milestone Pharmaceuticals, based in Quebec and North Carolina, is a clinical-stage biopharmaceutical company focused on the treatment of cardiovascular indications.

Jefferies LLC is an American multinational independent investment bank and financial services company that is headquartered in New York City.

McCarthy Tétrault advised Jefferies Finance with a team led by Andrew Parker that included Charles-Antoine Souliere and Vincent Laurin.